Biomarin Pharmaceutical BMRN
$60.41 −$1.01 (-1.64%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $60.02 -0.65%
Open$61.53
Prev close$61.42
Day range$59.84 – $62.01
Volume6.06M
Market cap$11.70B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.02B+32.0% YoY
Operating profit$205.65M+18.0% YoY
Net profit-$122.83M-299.5% YoY
Diluted EPS-$0.63-293.8% YoY
Free cash flow$164.16M-51.0% YoY
Operating cash flow$188.21M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin76.0%
Operating margin4.9%
Net margin-0.5%
Return on equity-0.3%
Return on assets-0.2%
Return on invested capital0.3%
Current ratio2.44
Liabilities / assets45.9%
Cash & investments$736.01M
Total debt$4.17B
Net cash (debt)-$3.44B
Free cash flow / sales15.2%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.02B | $989.71M | $766.21M | $3.22B | $874.57M |
| Total Operating Revenue | $1.02B | $989.71M | $766.21M | $3.22B | $874.57M |
| Cost of Revenue | $205.42M | $202.80M | $195.00M | $717.44M | $275.71M |
| Gross Profit | $819.23M | $786.91M | $571.21M | $2.50B | $598.86M |
| Operating Expense | $613.58M | $675.94M | $441.58M | $2.09B | $864.42M |
| Selling and Admin Expenses | $333.60M | $395.50M | $258.30M | $1.15B | $446.20M |
| -Selling & Marketing Expense | $148.90M | $142.20M | $124.90M | $530.20M | $174.20M |
| -General & Admin Expense | $184.70M | $253.30M | $133.40M | $622.80M | $272.00M |
| Research & Development | $180.53M | $206.95M | $178.80M | $921.93M | $413.38M |
| Depreciation & Amortization & Depletion | $99.46M | $73.49M | $4.48M | $19.39M | $4.85M |
| -Depreciation & Amortization | $99.46M | $73.49M | $4.48M | $19.39M | $4.85M |
| Operating Profit | $205.65M | $110.97M | $129.63M | $409.50M | -$265.57M |
| Net Non-Operating Interest Income (Expense) | -$51.00M | -$52.82M | $7.60M | $64.01M | $16.43M |
| Non-Operating Interest Income | $4.63M | $10.48M | $22.56M | $74.90M | $19.21M |
| Non-Operating Interest Expense | $55.63M | $63.30M | $14.96M | $10.90M | $2.78M |
| Other Income (Expense) | -$286.38M | $3.28M | $3.96M | $9.00M | $221.99M |
| Special Income (Charges) | -$287.69M | – | – | $0.00 | $220.96M |
| -Less:Other Special Charges | $287.69M | – | – | – | – |
| Other Non-Operating Income (Expenses) | $1.31M | $3.28M | $3.96M | $9.00M | $1.03M |
| Pretax Profit | -$131.77M | $61.38M | $141.20M | $482.48M | -$27.15M |
| Tax | -$8.94M | $16.62M | $35.68M | $133.58M | $19.42M |
| Net Profit | -$122.83M | $44.76M | $105.53M | $348.90M | -$46.57M |
| Profit from Continuing Operations | -$122.83M | $44.76M | $105.53M | $348.90M | -$46.57M |
| Net Income to Parent Company | -$122.83M | $44.76M | $105.53M | $348.90M | -$46.57M |
| Net Income to Common Stockholders | -$122.83M | $44.76M | $105.53M | $348.90M | -$46.57M |
| Basic EPS | -$0.63 | $0.23 | $0.55 | $1.82 | -$0.24 |
| Diluted EPS | -$0.63 | $0.23 | $0.54 | $1.80 | -$0.24 |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $11.57B | $11.72B | $8.59B | $7.59B | $7.59B |
| Total Current Assets | $3.92B | $3.97B | $4.61B | $3.95B | $3.95B |
| Cash and Cash Equivalents & Short-Term Investments | $736.01M | $874.01M | $2.22B | $1.56B | $1.56B |
| -Cash and Cash Equivalents | $736.01M | $874.01M | $2.22B | $1.31B | $1.31B |
| -Short Term Investments | $0.00 | $0.00 | $0.00 | $248.93M | $248.93M |
| Receivables | $1.08B | $1.06B | $903.91M | $908.21M | $908.21M |
| -Accounts Receivable | $1.08B | $1.06B | $903.91M | $908.21M | $908.21M |
| Inventory | $1.80B | $1.78B | $1.27B | $1.30B | $1.30B |
| Other Current Assets | $312.21M | $254.05M | $205.50M | $185.78M | $185.78M |
| Total Non-Current Assets | $7.65B | $7.75B | $3.99B | $3.64B | $3.64B |
| Net PPE | $980.08M | $989.99M | $958.07M | $952.51M | $952.51M |
| -Gross PPE | $2.11B | $2.10B | $2.05B | $2.03B | $2.03B |
| -Accumulated Depreciation | -$1.13B | -$1.11B | -$1.09B | -$1.07B | -$1.07B |
| Investments and Advances | $0.00 | $0.00 | $0.00 | $492.24M | $492.24M |
| Goodwill and Other Intangible Assets | $5.44B | $5.54B | $400.86M | $410.04M | $410.04M |
| -Goodwill | $666.37M | $655.75M | $196.20M | $196.20M | $196.20M |
| -Other Intangible Assets | $4.78B | $4.88B | $204.66M | $213.84M | $213.84M |
| Non-Current Deferred Assets | $897.79M | $888.58M | $1.50B | $1.51B | $1.51B |
| Other Non-Current Assets | $327.11M | $338.14M | $1.13B | $277.05M | $277.05M |
| Total Liabilities | $5.31B | $5.40B | $2.38B | $1.51B | $1.51B |
| Total Current Liabilities | $1.60B | $1.66B | $793.15M | $759.03M | $759.03M |
| Payables | $385.38M | $675.14M | $582.79M | $491.33M | $491.33M |
| -Accounts Payable | $130.72M | $406.98M | $395.47M | $312.77M | $312.77M |
| -Total Tax Payable | $18.92M | $9.14M | $3.01M | $3.67M | $3.67M |
| -Other Payable | $235.74M | $259.03M | $184.31M | $174.89M | $174.89M |
| Current Accrued Expenses | $509.78M | $60.56M | $16.75M | $8.59M | $8.59M |
| Short-Term Debt and Capital Lease Obligation | $675.24M | $674.26M | $9.32M | $8.69M | $8.69M |
| -Current Debt | $658.72M | $658.20M | – | – | – |
| -Current Capital Lease Obligation | $16.52M | $16.06M | $9.32M | $8.69M | $8.69M |
| Other Current Liabilities | $34.43M | $33.53M | $31.68M | $31.01M | $31.01M |
| Total Non-Current Liabilities | $3.71B | $3.74B | $1.59B | $747.99M | $747.99M |
| Long Term Debt and Capital Lease Obligation | $3.51B | $3.53B | $1.43B | $597.18M | $597.18M |
| -Long Term Debt | $3.51B | $3.53B | $1.43B | $597.18M | $597.18M |
| Other Non-Current Liabilities | $193.40M | $209.82M | $155.48M | $150.82M | $150.82M |
| Total Equity | $6.26B | $6.32B | $6.21B | $6.09B | $6.09B |
| Stockholders' Equity | $6.26B | $6.32B | $6.21B | $6.09B | $6.09B |
| Capital Stock | $194,000.00 | $194,000.00 | $193,000.00 | $192,000.00 | $192,000.00 |
| -Common Stock | $194,000.00 | $194,000.00 | $193,000.00 | $192,000.00 | $192,000.00 |
| Additional Paid-In Capital | $6.09B | $6.04B | $5.97B | $5.96B | $5.96B |
| Retained Earnings | $181.66M | $304.50M | $259.73M | $154.21M | $154.21M |
| Gains/Losses Not Affecting Retained Earnings | -$4.01M | -$8.78M | -$4.24M | -$13.47M | -$13.47M |
| Other Equity Interests | -$10.85M | -$11.23M | -$10.45M | -$10.51M | -$10.51M |
| -Available for Sale Securities | – | – | – | $492.24M | $492.24M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $188.21M | $168.11M | $220.65M | $827.99M | $99.64M |
| Net cash flow from continuing operations | $188.21M | $168.11M | $220.65M | $827.99M | $99.64M |
| Net Income from Continuing Operations | -$122.83M | $44.76M | $105.53M | $348.90M | -$46.57M |
| Gain/Loss from Continuing Operations | -$4.33M | -$10.76M | $6.71M | $4.46M | $4.22M |
| Depreciation & Depletion & Amortization | $130.47M | $97.64M | $16.41M | $79.56M | $20.44M |
| Deferred Tax | -$29.75M | -$6.96M | $9.22M | $48.74M | $613,000.00 |
| Other Non-Cash Items | $283.34M | $21.67M | $712,000.00 | $219.17M | $1.64M |
| Change in Working Capital | -$137.41M | -$54.39M | $39.07M | -$293.66M | -$164.05M |
| -Change in Receivables | -$14.43M | -$38.85M | -$7.16M | -$228.05M | -$120.68M |
| -Change in Inventory | -$13.96M | -$32.16M | $44.49M | -$116.93M | -$18.13M |
| -Change in Payables and Accrued Expense | -$78.94M | $23.17M | $3.10M | $66.14M | -$53.34M |
| -Change in Other Current Assets | -$26.93M | -$4.52M | -$10.07M | -$29.68M | $35.12M |
| -Change in Other Current Liabilities | -$3.16M | -$2.04M | $8.70M | $14.87M | -$7.02M |
| Net cash flow from investing | -$306.90M | -$5.10B | $725.53M | -$414.24M | -$42.45M |
| Net Cash Flow from Continuing Investing Activities | -$306.90M | -$5.10B | $725.53M | -$414.24M | -$42.45M |
| Net PPE Purchase and Sale | -$28.29M | -$28.82M | -$20.92M | -$103.04M | -$40.72M |
| Net Intangibles Purchase and Sale | $4.24M | – | – | -$7.94M | -$2.37M |
| Net Business Purchase and Sale | -$277.88M | – | – | -$285.19M | $0.00 |
| Net Investment Purchase and Sale | $0.00 | $0.00 | $741.49M | -$18.07M | $641,000.00 |
| Financing Cash Flow | -$18.83M | $2.74B | $813.17M | -$42.39M | $3.16M |
| Net Cash Flow from Continuing Financing Activities | -$18.83M | $2.74B | $813.17M | -$42.39M | $3.16M |
| Net Issuance Payments Of Debt | -$15.00M | $2.80B | $850.00M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $0.00 | – | – | $14.46M | $6.75M |
| Net Other Financing Charges | -$3.83M | -$68.28M | -$36.83M | -$56.85M | -$3.59M |
| Ending Cash Balance | $736.01M | $874.01M | $3.07B | $1.31B | $1.31B |
| Net Change in Cash | -$137.51M | -$2.20B | $1.76B | $371.36M | $60.35M |
| Beginning Cash Balance | $874.01M | $3.07B | $1.31B | $942.84M | $1.25B |
| Effect of Exchange Rate Changes | -$487,000.00 | -$3.04M | $1.41M | -$2.52M | $1.22M |
| Free Cash Flow | $164.16M | $133.86M | $199.73M | $717.02M | $56.55M |
| Net Other Investing Changes | – | $0.00 | $4.97M | – | – |
No comments yet — be the first to weigh in on BMRN.
Sign in to join the discussion.